Published in Sleep on August 01, 1991
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
Circadian and sleep disorders in Parkinson's disease. Exp Neurol (2012) 1.03
Strategies for the treatment of restless legs syndrome. Neurotherapeutics (2012) 1.03
Time structure analysis of leg movements during sleep in REM sleep behavior disorder. Sleep (2007) 0.88
Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence. Transl Neurodegener (2012) 0.85
Restless legs syndrome and Parkinson's disease: is there an etiologic link? J Neurol (2006) 0.83
Restless legs and periodic leg movements in sleep syndromes. J Neurol (1997) 0.80
Restless leg syndrome: is it a real problem? Ther Clin Risk Manag (2006) 0.78
Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns. BMC Neurol (2008) 0.77
Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat (2009) 0.77
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes. Core Evid (2005) 0.75
Schizophrenia and sleep disorders: links, risks, and management challenges. Nat Sci Sleep (2017) 0.75
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature (2001) 8.95
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J (1998) 3.13
A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol (1991) 3.13
Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci U S A (1982) 3.11
Modulation of insulin activities by leptin. Science (1996) 2.92
The human interferon alpha/beta receptor: characterization and molecular cloning. Cell (1994) 2.63
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem (1989) 2.35
Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 2.24
Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron (1997) 2.20
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci U S A (1979) 2.03
Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol (1998) 2.00
In situ hybridization analysis of anterior pituitary hormone gene expression during fetal mouse development. J Histochem Cytochem (1994) 1.95
Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci (1998) 1.91
Unexpected power-law stress relaxation of entangled ring polymers. Nat Mater (2008) 1.91
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 1.86
Isolation and characterization of the opioid peptides from rat pituitary: beta-lipotropin. Proc Natl Acad Sci U S A (1977) 1.86
Localized myokymia caused by peripheral nerve injury. Arch Neurol (1976) 1.61
Glutamate dehydrogenase deficiency in patients with olivopontocerebellar atrophy. Neurology (1983) 1.51
Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J Clin Invest (2001) 1.51
The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood (1988) 1.47
Isolation and characterization of the opioid peptides from rat pituitary: beta-endorphin. Proc Natl Acad Sci U S A (1977) 1.47
Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med (2001) 1.44
Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem (1999) 1.43
Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry (1993) 1.42
Comorbidities associated with overactive bladder. Am J Manag Care (2000) 1.41
Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain. J Biol Chem (1991) 1.41
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Posttraumatic delayed sleep phase syndrome. Neurology (2000) 1.41
The syndrome of primary orthostatic hypotension. Brain (1969) 1.41
Median-ulnar anastomosis to thenar, hypothenar, and first dorsal interosseous muscles: collision technique confirmation. Muscle Nerve (1997) 1.40
Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. Nat Neurosci (1998) 1.39
Human leukocyte interferon: isolation and characterization of several molecular forms. Arch Biochem Biophys (1981) 1.38
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.37
The interaction of visual and proprioceptive inputs in pointing to actual and remembered targets in Parkinson's disease. Neuroscience (2001) 1.37
The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem (1994) 1.32
Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay. EMBO J (1983) 1.31
Monoclonal antibodies to human alpha-interferon and their use for affinity chromatography. J Immunol (1982) 1.30
Amino acid sequence of a human leukocyte interferon. Proc Natl Acad Sci U S A (1981) 1.29
Binding assay for opioid peptides with neuroblastoma x glioma hybrid cells: specificity of the receptor site. Brain Res (1978) 1.29
Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem (1995) 1.27
Closed-chest electrode-catheter technique for His bundle ablation in dogs. Am J Physiol (1981) 1.24
The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol Psychiatry (2004) 1.22
Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol (2001) 1.21
Pure motor hemiplegia due to pyramidal infarction. Arch Neurol (1975) 1.21
A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology (1996) 1.21
Procedural motor learning in Parkinson's disease. Exp Brain Res (2001) 1.20
Affinity chromatography of human fibroblast interferon (IFN-beta 1) by monoclonal antibody columns. J Gen Virol (1983) 1.20
Painless legs and moving toes: a syndrome related to painful legs and moving toes? Mov Disord (1993) 1.19
The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci (1999) 1.18
High molecular weight opioid-containing proteins in striatum. Proc Natl Acad Sci U S A (1978) 1.18
The human interferon-gamma receptor. Purification, characterization, and preparation of antibodies. J Biol Chem (1987) 1.18
Control of voluntary and reflexive saccades in Parkinson's disease. Exp Brain Res (1999) 1.16
"Alpha-like" rhythms in electroencephalograms in coma after cariac arrest. Neurology (1975) 1.16
Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology (2002) 1.16
Primary sleep apnoea syndrome. J Neurol Neurosurg Psychiatry (1981) 1.15
Purification to homogeneity of camel pituitary pro-opiocortin, the common precursor of opioid peptides and corticotropin. Proc Natl Acad Sci U S A (1979) 1.12
Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer (1983) 1.12
Leptin induces angiopoietin-2 expression in adipose tissues. J Biol Chem (2001) 1.10
Characterization of pro-opiocortin, a precursor to opioid peptides and corticotropin. Proc Natl Acad Sci U S A (1978) 1.10
An antiviral soluble form of the LDL receptor induced by interferon. Science (1993) 1.10
Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension (2001) 1.09
Amino-terminal amino acid sequence of human leukocyte interferon. Proc Natl Acad Sci U S A (1980) 1.09
Ligand-induced association of the type I interferon receptor components. Mol Cell Biol (1995) 1.08
Ethanol-conditioned place preference is reduced in dopamine D2 receptor-deficient mice. Pharmacol Biochem Behav (2000) 1.08
Lack of operant ethanol self-administration in dopamine D2 receptor knockout mice. Psychopharmacology (Berl) (2000) 1.07
Tongue and limb myokymia in amyotrophic lateral sclerosis. Neurology (1999) 1.06
Harvesting the human genome: the Israeli perspective. Isr Med Assoc J (2000) 1.06
Human leukocyte interferon purified to homogeneity. Science (1978) 1.05
Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons. Proc Natl Acad Sci U S A (1981) 1.05
Frequent occurrence of myoclonus while awake and at rest, body rocking and marching in place in a subpopulation of patients with restless legs syndrome. Acta Neurol Scand (1988) 1.05
Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord (1999) 1.05
The structure of human interferons. Biochim Biophys Acta (1982) 1.04
Progressive dialytic encephalopathy. J Neurol Neurosurg Psychiatry (1976) 1.04
Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol Psychiatry (2011) 1.04
Electrophysiological study of hemiplegia. Motor nerve conduction velocity, brachial plexus latency, and electromyography. Arch Neurol (1978) 1.03
High and low potency interferon-alpha subtypes induce (2'-5') oligoadenylate synthetase with similar efficiency. Virology (1983) 1.03
Sleep apnea in narcolepsy. Sleep (1986) 1.02
K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol (1999) 1.02
An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci U S A (2001) 1.01
Diabetic amyotrophy: current concepts. Semin Neurol (1996) 1.01
Positron emission tomographic studies in restless legs syndrome. Mov Disord (1999) 1.01
Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep (1993) 1.00
Laryngeal epithelial thickness: a comparison between optical coherence tomography and histology. Clin Otolaryngol (2009) 1.00
A 51-year-old woman with disorientation and amnesia. Lancet (1999) 1.00
Identification of DNA elements cooperatively activating proopiomelanocortin gene expression in the pituitary glands of transgenic mice. Mol Cell Biol (1992) 0.99
Clinical presentation and neuropharmacology of restless legs syndrome. Clin Neuropharmacol (1987) 0.99
Palatal myoclonus and rhythmic ocular movements: a polygraphic study. Neurology (1969) 0.99
Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors. J Psychopharmacol (2009) 0.99
Authentic cell-specific and developmentally regulated expression of pro-opiomelanocortin genomic fragments in hypothalamic and hindbrain neurons of transgenic mice. J Neurosci (1998) 0.98
Organization of voluntary movement. Curr Opin Neurobiol (1991) 0.98
Pointing to remembered targets in 3-D space in Parkinson's disease. Motor Control (1998) 0.98
Two antiviral proteins from tobacco: purification and characterization by monoclonal antibodies to human beta-interferon. Proc Natl Acad Sci U S A (1990) 0.97
Engineering zucchini yellow mosaic potyvirus as a non-pathogenic vector for expression of heterologous proteins in cucurbits. J Biotechnol (2001) 0.97
Type I and Type II interferon receptors. J Interferon Res (1984) 0.97
Viruslike particles in granulomatous angiitis of the central nervous system. Neurology (1976) 0.97
Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord (2001) 0.97